Altretamine

U.S. BRAND NAMES — Hexalen®

PHARMACOLOGIC CATEGORY
Antineoplastic Agent, Miscellaneous

DOSING: ADULTS — Refer to individual protocols.

Ovarian cancer: Oral: 260 mg/m2/day in 4 divided doses for 14 or 21 days of a 28-day cycle
Alternatively (unlabeled use): 4-12 mg/kg/day in 3-4 divided doses for 21-90 days
Alternatively (unlabeled use): 240-320 mg/m2/day in 3-4 divided doses for 21 days, repeated every 6 weeks
Alternatively (unlabeled use): 150 mg/m2/day in 3-4 divided doses for 14 days of a 28-day cycle

DOSING: ELDERLY — Refer to adult dosing.

DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Gelcap:
Hexalen®: 50 mg

DOSAGE FORMS: CONCISE
Gelcap:
Hexalen®: 50 mg

GENERIC EQUIVALENT AVAILABLE — No

ADMINISTRATION — Administer total daily dose as 3-4 divided doses after meals and at bedtime.

USE — Palliative treatment of persistent or recurrent ovarian cancer

ADVERSE REACTIONS SIGNIFICANT
>10%:
Central nervous system: Peripheral sensory neuropathy (31%; moderate-to-severe 9%), neurotoxicity (21%; may be progressive and dose-limiting)
Gastrointestinal: Nausea/vomiting (33% to 70%; severe 1%), diarrhea (48%)
Hematologic: Anemia (33%), leukopenia (5% to 15%; grade 4: 1%), neutropenia

1% to 10%:
Central nervous system: Fatigue (1%), seizure (1%)
Gastrointestinal: Stomach cramps, anorexia (1%)
Hematologic: Thrombocytopenia (9%)
Hepatic: Alkaline phosphatase increased (9%)

<1% (Limited to important or life-threatening): Alopecia, ataxia, depression, dizziness, hepatotoxicity, mood disorders, pruritus, rash, tremor, vertigo

CONTRAINDICATIONS — Hypersensitivity to altretamine or any component of the formulation; pre-existing severe bone marrow suppression or severe neurologic toxicity; pregnancy

WARNINGS / PRECAUTIONS
Box warnings: Bone marrow suppression: See "Concerns related to adverse effects" below. Experienced physician: See "Other warnings/precautions" below. Neurotoxicity: See "Concerns related to adverse effects" below.

Special handling: Hazardous agent: Use appropriate precautions for handling and disposal.

Concerns related to adverse effects: Bone marrow suppression: [U.S. Boxed Warning]: Peripheral blood counts should be done routinely before and after drug therapy; bone marrow suppression is common. Use with caution in patients previously treated with other myelosuppressive drugs. Neurotoxicity: [U.S. Boxed Warning]: Neurologic examinations should be done routinely before and after drug therapy; neurotoxicity is common. USe with caution in patients with pre-existing neurotoxicity.

Disease-related concerns: Hepatic impairment: Use with caution in patients with hepatic impairment. Renal impairment: Use with caution in patients with renal impairment.

Special populations: Pediatrics: Safety and efficacy have not been established in children.

Other warnings/precautions: Experienced physician: [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.

DRUG INTERACTIONS
MAO inhibitors: Altretamine may enhance the orthostatic effect of MAO inhibitors.

Pyridoxine: May diminish the therapeutic effect of altretamine; concurrent use not recommended.

Tricyclic antidepressants: Altretamine may enhance the orthostatic effect of tricyclic antidepressants.

PREGNANCY RISK FACTOR — D (show table)

PREGNANCY IMPLICATIONS — Teratogenic effects were noted in animal studies. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should avoid becoming pregnant while on therapy.

LACTATION — Excretion in breast milk unknown/not recommended

BREAST-FEEDING CONSIDERATIONS — Due to the potential toxicity in the nursing infant, breast-feeding is not recommended.

DIETARY CONSIDERATIONS — Should be taken after meals at bedtime.

MONITORING PARAMETERS — CBC with differential, liver function tests; neurologic examination

TOXICOLOGY / OVERDOSE COMPREHENSIVE — Symptoms include nausea, vomiting, peripheral neuropathy, and severe bone marrow suppression. Treatment is symptom-directed and supportive.

CANADIAN BRAND NAMES — Hexalen®

INTERNATIONAL BRAND NAMES — Hexalen (AU, BG, CA, CN, GB, IE, IL, JP, NZ, SE, TH); Hexastat (DK, FR, NO, PT); Hexinawas (ES)

MECHANISM OF ACTION — Although altretamine's clinical antitumor spectrum resembles that of alkylating agents, the drug has demonstrated activity in alkylator-resistant patients. The drug selectively inhibits the incorporation of radioactive thymidine and uridine into DNA and RNA, inhibiting DNA and RNA synthesis; reactive intermediates covalently bind to microsomal proteins and DNA; can spontaneously degrade to demethylated melamines and formaldehyde which are also cytotoxic.

PHARMACODYNAMICS / KINETICS
Absorption: Well absorbed (75% to 89%)

Distribution: Highly concentrated hepatically and renally; low in other organs

Protein binding: 50% to 94%

Metabolism: Hepatic; rapid and extensive demethylation to active metabolites (pentamethylmelamine and tetramethylmelamine)

Half-life elimination: 13 hours

Time to peak, plasma: 0.5-3 hours

Excretion: Urine (90%, <1% as unchanged drug)

PATIENT INFORMATION — Report any numbness or tingling in extremities. Nausea and vomiting may occur.

(For additional information see "Altretamine: Patient drug information")


Use of UpToDate is subject to the Subscription and License Agreement. REFERENCES 1. Ames, MM. Hexamethylmelamine: Pharmacology and Mechanism of Action. Cancer Treat Rev 1991; 18(Suppl A):3.
2. Bruckner, HW, Schleifer, SJ. Orthostatic Hypotension as a Complication of Hexamethylmelamine Antidepressant Interaction. Cancer Treat Rep 1983; 67:516.
3. Damia, G, D'Incalci, M. Clinical Pharmacokinetics of Altretamine. Clin Pharmacokinet 1995; 28:439.
4. Hahn, DA, Black, C. Hexamethylamine: A Review. Drug Intell Clin Pharm 1980; 14:541.
5. Hansen, LA, Hughes, TE. Altretamine. DICP 1991; 25:146.
6. Lee, CR, Faulds, D. Altretamine. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Cancer Chemotherapy. Drugs 1995; 49:932.
7. Manetta, A, Mac Neill, C, Lyter, JA, et al. Hexamethylmelamine as a Single Second-Line Agent in Ovarian Cancer. Gynecol Oncol 1990; 36:93.
8. Sutton, GP. Secondary Therapy for Epithelial Ovarian Cancer - 1994. Semin Oncol 1994; 21(4 Suppl 7):32.
9. Thigpen, JT, Vance, RB, Khansur, T. Second-Line Chemotherapy for Recurrent Carcinoma of the Ovary. Cancer 1993; 71(4 Suppl):1559.